Biomarker ID | 1110 |
PMID | 23582881 |
Year | 2013 |
Biomarker | Galectin-3-binding protein |
Biomarker Basis | Concentration Based |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Upregulated in Progression Free Survival |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Progression Free Survival (PFS) at 12 weeks |
Type of Biomarker | Prognostic |
Cohort | A total of 37 chemotherapy-naive patients with mCRPC and progressive disease were recruited to this study |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p = 0.009 |
Method Used | NA |
Clinical | Yes |
Remarks | The primary end point was progression- free survival (PFS) at 12 weeks: defined as the absence of prostate-specific antigen (PSA), radiographic progression, or clinical progression. |
Clinical Trial Number | NCT00976755 |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |